Net Income for Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's current net income (TTM) is $1.29B USD. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
BIIB
Currently viewingNet IncomeSwitch metric
TTM (last 4 quarters)
$1.29B
YoY change
-20.8%
5Y CAGR
-20.2%
Peak year (2019)
$5.89B
Cumulative net income
$44.40B
Net Income history chart for Biogen (BIIB) from 1985 to 2025
Net Income history table for Biogen (BIIB) from 1985 to 2025
| Fiscal year | Period ended | Reported | Net Income | YoY |
|---|---|---|---|---|
| 2025 | $1.29B | -20.8% | ||
| 2024 | $1.63B | +40.6% | ||
| 2023 | $1.16B | -61.9% | ||
| 2022 | $3.05B | +95.8% | ||
| 2021 | $1.56B | -61.1% | ||
| 2020 | $4.00B | -32.1% | ||
| 2019 | $5.89B | +32.9% | ||
| 2018 | $4.43B | +74.5% | ||
| 2017 | $2.54B | -31.4% | ||
| 2016 | $3.70B | +4.4% | ||
| 2015 | $3.55B | +20.9% | ||
| 2014 | $2.93B | +57.6% | ||
| 2013 | $1.86B | +34.9% | ||
| 2012 | $1.38B | +11.8% | ||
| 2011 | $1.23B | +22.8% | ||
| 2010 | $1.01B | +3.6% | ||
| 2009 | $970.13M | +23.9% | ||
| 2008 | $783.17M | +22.7% | ||
| 2007 | $638.17M | +193.4% | ||
| 2006 | $217.51M | +35.3% | ||
| 2005 | $160.71M | +540.6% | ||
| 2004 | $25.09M | -102.9% | ||
| 2003 | -$875.10M | -690.9% | ||
| 2002 | $148.09M | -45.7% | ||
| 2001 | $272.68M | -18.3% | ||
| 2000 | $333.58M | +51.3% | ||
| 1999 | $220.45M | +58.9% | ||
| 1998 | $138.70M | +55.5% | ||
| 1997 | $89.17M | +120.0% | ||
| 1996 | $40.53M | +616.1% | ||
| 1995 | $5.66M | -215.6% | ||
| 1994 | -$4.90M | -115.1% | ||
| 1993 | $32.40M | -15.4% | ||
| 1992 | $38.30M | +431.9% | ||
| 1991 | $7.20M | -6.5% | ||
| 1990 | $7.70M | +140.6% | ||
| 1989 | $3.20M | -366.7% | ||
| 1988 | -$1.20M | -94.7% | ||
| 1987 | -$22.60M | -19.9% | ||
| 1986 | -$28.20M | +47.6% | ||
| 1985 | -$19.10M | — |
Net Income values are taken from Biogen's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Biogen (BIIB) net income is $1.29B – declined 20.8% year-over-year.
Across 2020–2025 (5 years), Biogen net income produced a CAGR of -20.2% – with a net decline across the window.
Biogen net income plunged from $5.89B in 2019 to $1.29B in 2025, a 78.0% drawdown.
Across the available history, net income reached its high of $5.89B in 2019 and its low of -$875.10M in 2003.
Among 8 Healthcare peers, Biogen (BIIB) ranks 9th; the peer median for net income is $15.15B.
Biogen Net Income by Year
Biogen Net Income 2025: $1.29B
Biogen net income in 2025 was $1.29B, declined 20.8% below 2024.
Biogen Net Income 2024: $1.63B
Biogen net income in 2024 was $1.63B, surged 40.6% from 2023.
Biogen Net Income 2023: $1.16B
Biogen net income in 2023 was $1.16B, plunged 61.9% below 2022.
Biogen Net Income 2022: $3.05B
Biogen net income in 2022 was $3.05B, surged 95.8% from 2021.
Biogen Net Income 2021: $1.56B
Biogen net income in 2021 was $1.56B.
See more financial history for Biogen (BIIB).
Sector peers — Net Income
Companies in the same sector as Biogen, ranked by their latest net income.
| Company | Net Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $102.43B | Healthcare |
| Johnson & Johnson (JNJ) | $26.80B | Healthcare |
| Eli Lilly and Company (LLY) | $20.64B | Healthcare |
| Merck & Co., Inc. (MRK) | $18.25B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $12.06B | Healthcare |
| AstraZeneca PLC (AZN) | $10.26B | Healthcare |
| Amgen Inc. (AMGN) | $7.71B | Healthcare |
| AbbVie Inc. (ABBV) | $4.23B | Healthcare |
Frequently asked questions
What is Biogen's net income?
- Latest reported net income for Biogen (BIIB) is $1.29B (period ending December 31, 2025).
How has Biogen net income changed year-over-year?
- Biogen (BIIB) net income changed -20.8% year-over-year on the latest annual filing.
What is the long-term growth rate of Biogen net income?
- Biogen (BIIB) net income compound annual growth rate is -20.2% over the most recent 5 years available.
When did Biogen net income hit its highest annual value?
- Biogen net income reached its highest annual value of $5.89B in 2019.
What was Biogen net income in 2024?
- Biogen (BIIB) net income in 2024 was $1.63B.
What was Biogen net income in 2025?
- Biogen (BIIB) net income in 2025 was $1.29B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
BIIB Overview
Company profile, financial tools, and key metrics
BIIB Revenue Counter
Earns $311.09 every second. See per minute, hour, and day.
BIIB Earnings Counter
Earns $41.01 per second net profit. See per minute, hour, and day.
BIIB Economic Scale
Exceeds Bermuda's GDP. Compare with world economies.
BIIB What If Invested
What if you had invested $1,000? See historical returns from any date.
BIIB How It Makes Money
Discover visual breakdown of $9.81B in revenue — where it comes from and where it goes.
BIIB Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BIIB Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BIIB Daily Price Character
Explosive · 48.1% historical win rate (green days). Streaks & record days.
BIIB Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BIIB Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.